Evaluation of selected honey and one of its phenolic constituent eugenol against L1210 lymphoid leukemia by Jaganathan, Saravana Kumar et al.
Research Article
Evaluation of Selected Honey and One of Its Phenolic
Constituent Eugenol against L1210 Lymphoid Leukemia
Saravana Kumar Jaganathan,1 Dilip Mondhe,2 Z. A. Wani,2 and Eko Supriyanto1
1 IJN-UTM Cardiovascular Engineering Centre, Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia,
81310 Skudai, Johor, Malaysia
2 Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir 180 001, India
Correspondence should be addressed to Saravana Kumar Jaganathan; jaganathaniitkgp@gmail.com
Received 18 May 2014; Accepted 24 August 2014; Published 9 September 2014
Academic Editor: Tsutomu Hatano
Copyright © 2014 Saravana Kumar Jaganathan et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
People affected with leukemia are on the rise and several strategies were employed to thwart this deadly disease. Recent decade of
research focuses on phenolic constituents as a tool for combating various inflammatory, cancer, and cardiac diseases. Our research
showed honey and its phenolic constituents as crusaders against cancer. In this work, we explored the antileukemic activity of
selected honey and one of its phenolic constituent eugenol against L1210 leukemia animal model. Results of this experiment showed
that the selected honey samples as well as eugenol after intraperitoneal injection could not increase themedian survival time (MST)
of animals. Further, there was only slight marginal increase in the %T/C values of honey and eugenol treated groups. The number
of phenolics present in the honey may not be a prime factor to promote antileukemic effect since there was no difference in the
MST of two different honeys tested. This study limits the use of selected honey and eugenol against leukemia animal model.
1. Introduction
Leukemia is widely called blood cancer and it is characterized
by uncontrolled growth of blood cells produced in the bone
morrow. It has estimated that 6020 people (3,140 inmales and
2,880 in females) will be affected and 1440 people will die
of leukemia in 2014 [1]. This alarming rate necessitates the
search for novel antileukemic agents gaining momentum.
Recent research from our laboratory showed honey con-
taining higher phenolic constituents is potent in inhibiting
colon cancer cells [2–4]. Also one of our recent works
deciphered the apoptotic mechanism of eugenol against
colon cancer cells [5, 6]. To further advance our research,
we screened the in vivo antitumour efficiency of two
selected honeys (Sample C possessing higher phenolic con-
tent (65.06% gallic acid equivalent (GAE)) and Sample Bwith
lower phenolic content (29.96%GAE) [3] and eugenol against
L1210 lymphoid leukemia animal model.
L1210 are derived frommouse lymphocytic leukemia cells
originating from the ascitic fluid of 8-month-old femalemice.
Although it is lymphocytic B-cells they appear more like
lymphoblasts in morphology. These cells are widely used
in cytotoxic assays of chemotherapeutic agents. Kim et al.,
1994, showed adenosine resulted in apoptosis of L1210 cells.
Further, they showed apoptosis process was accompanied by
distinctmorphological changes including chromatin conden-
sation and blebbing of plasma membranes [7]. Frequently,
these cells are also injected in animals to develop an in vivo
animal model bearing lymphocytic leukemia cells. This in
vivo animalmodel appears to be a putative tool for investigat-
ing the antileukemic effect of anticancer compounds. Some of
the studies used this model for studying antileukemic activity
of N4-alkyl-1-beta-D-arabinofuranosyl cytosines, epirubicin,
and so forth [8, 9].
This work reports the results of antitumor effects of the
selected honey samples and eugenol against L1210 lymphoid
leukemia animal model. This work will determine whether
the number of phenolic constituents will have any effect on
the antitumor activity of honey against lymphoid leukemia
animal model.
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Table 1: Antileukemic activity of selected honey and eugenol.
Treatment groups Median survival time % 𝑇/𝐶 Inference
Sample B (50% v/v i.p.) 8.0 days 102.56 Nonsignificant activity
Sample C (50% v/v) 8.16 days 104.61 Nonsignificant activity
Eugenol (100mg/kg i.p.) 8.6 days 110.25 Nonsignificant activity
5-FU (20mg/kg i.p.) 13.0 days 166.66 Significant activity
Control (NS 0.2mL i.p.) 7.8 days
2. Materials and Methods
2.1. Animals Used
Model: L1210 lymphoid leukemia
Sample: Sample C, Sample B, and eugenol
Animals: CDF1
Sex: male
Weight: 18–23 g.
2.2. Experimental Method. L1210 lymphoid leukemia cells
grown in the peritoneal cavity of DBA/2 female mice were
collected from the animal harboring 6-7-day-old ascites. For
testing, CDF1 males were used. 5 × 105 cells were injected
intraperitoneally in 30 CDF1 males weighing 18–23 g on day
0. The next day, animals were randomized and divided into
five groups, containing 6 animals each. Groups I, II, and
III were treated with Sample C, Sample B, and eugenol at
the doses of 50% v/v (i.p.), 50% v/v (i.p.), and 100mg/kg
(i.p.), respectively, for 9 consecutive days. Group IV was
treated with 5-fluorouracil (20mg/kg) (i.p.) and it served as
positive control. The control group received 0.2mL normal
saline (i.p.) for 9 consecutive days.The animals in each group
were observed for mortality up to day 18 and the median
survival time of animals in each group was calculated. The
antileukemic activity was assessed by use of the criterion
%T/C, where T was the median survival time (MST, days)
of the drug treated mice, bearing L1210 lymphoid leukemia,
and C was the median survival time (MST, days) of untreated
control animals, bearing the same leukemia.
3. Results
Results obtained for the in vivo antitumour activity of selected
honey samples and eugenol were listed in Table 1. From the
results, it can be inferred that median survival time (MST)
of all the honey samples tested did not show any significant
differences compared to the positive control. %T/C values
estimated for 5-FUwere 166.6, whereas for the honey samples
they were found to be 102.56, 104.61 for Sample B and Sample
C, respectively. For eugenol, they were found to be 110.25.
4. Discussion
Observed results are similar to our recently published work
which studied the effect of honey on Ehrlich solid carci-
noma [10]. Although Sample C was found to be potent in
inhibiting Ehrlich ascites, the preventive effect on Ehrlich
solid carcinoma was diminutive at the range of 4% tumor
inhibition. Phenolic content of Sample C and Sample B
was 65.06 Gallic acid equivalent (GAE) and 29.96 GAE,
respectively [3]. Inspite of their significant difference in
their phenolic content, %T/C values show barely discernible
difference between the two honey samples. Researchers had
identified some phenolic components of honey that have
been attributed to the antileukemic activity [11]. Hence,
we assume that qualitative nature of phenolic constituents
present in the honeymay play a vital role against the leukemia
but not the total phenolic content of honey.
Previous work from our laboratory showed eugenol at
a dose of 100mg/kg i./p. was able to inhibit the growth
of Ehrlich ascites by 28.88%. Moreover, it has been found
that eugenol (100mg/kg; i./p.) showed 24.35% tumor growth
inhibition of Ehrlich solid carcinoma. However, our results
with leukemia animalmodel are not promising. Although the
estimated %T/C andMST were higher for eugenol compared
to honey samples, they were not significant compared with
the positive control. However, eugenol has shown to be effec-
tive in inducing apoptosis in HL-60 leukemia cells through
reactive oxygen species (ROS) generation [12]. Hence, it
would be interesting for further studies to document the
effect of eugenol on HL-60 bearing animal model to further
validate eugenol as a possible candidate against leukemia.
In summary, this work evaluated the antitumor effect of
honey samples and eugenol against L1210 leukemia animal
model. Result showed both honey samples and eugenol dis-
played nonsignificant antileukemic activity compared with
the positive control.This result serves as an indicator that the
higher phenolic content of honey may not be always a prime
factor to promote antitumor effect in leukemia animalmodel.
Further apoptotic activity of eugenol in certain leukemia
cancer cell linesmaynot correlatewith the antileukemic effect
observed on L1210 animal model.
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